On This Page
- Background: The Evolution of GHRH Analogs
- Molecular Structure and DAC Technology
- Mechanism of Action: The GHRH Receptor Pathway
- Research Evidence and Evidence Table
- Domain-Specific Observations
- Pharmacokinetic Comparison: DAC vs. Non-DAC
- Limitations and Research Directions
- Related Research Compounds
- Where to Source CJC-1295 for Research
- Frequently Asked Questions
- Works Cited
Background: The Evolution of GHRH Analogs
Growth Hormone Releasing Hormone (GHRH) is a 44-amino acid hypothalamic peptide that serves as the primary driver for growth hormone (GH) secretion from the anterior pituitary. While researchers have long investigated endogenous GHRH for metabolic studies, its utility is limited by an extremely short plasma half-life (roughly 7 minutes) due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4).
The development of CJC-1295 followed the discovery of GRF 1-29 (Sermorelin), an active fragment of GHRH that retains full biological activity. Researchers sought to further enhance GRF 1-29 for sustained research use only (RUO) studies by introducing tetrasubstitutions and covalent binding technology. This resulted in a compound that could maintain elevated GH and IGF-1 concentrations for extended periods without the need for constant titration or frequency of administration common in early somatotropic models.
Molecular Structure and DAC Technology
CJC-1295 is structurally classified as a tetrasubstituted analog of the first 29 residues of human GHRH. The specific substitutions are:
- D-Ala at position 2: Enhances resistance to DPP-4 cleavage.
- Gln at position 8: Improves chemical stability.
- Ala at position 15: Enhances biological potency.
- Leu at position 27: Further protects against metabolic degradation.
The most distinctive feature of the variant known as CJC-1295 DAC is the addition of a lysine-maleimide Drug Affinity Complex (DAC) at the C-terminus. This group allows the peptide to form a covalent thioether bond with circulating serum albumin. Because albumin has a long systemic residence time, the peptide is protected from renal clearance and enzymatic attack, extending its half-life from minutes to several days [1].
Mechanism of Action: The GHRH Receptor Pathway
CJC-1295 operates as a highly selective GHRH receptor (GHRHR) agonist. Upon reaching the anterior pituitary, the peptide binds to GHRHR on somatotroph cells, initiating a Gs-protein coupled signaling cascade:
- Adenylyl Cyclase Activation: Binding triggers the conversion of ATP to cyclic adenosine monophosphate (cAMP).
- PKA Cascade: Elevated cAMP levels activate Protein Kinase A (PKA).
- GH Secretion: PKA facilitates the opening of calcium channels and the transcription of the growth hormone gene, leading to the exocytosis of GH-containing vesicles.
Unlike exogenous growth hormone administration, CJC-1295 stimulates the endogenous release mechanisms, which helps maintain the natural feedback loops within the hypothalamic-pituitary-somatotropic axis.
Research Evidence and Evidence Table
The efficacy of CJC-1295 has been investigated across multiple research domains, primarily focused on its impact on GH and IGF-1 levels.
Evidence Table: CJC-1295 Research Domains
| Research Domain | Observed Effects | Maturity of Evidence |
|---|---|---|
| Somatotropic Response | 2-10 fold increase in mean GH; 1.5-3 fold increase in IGF-1 | High (Clinical Trials) |
| Pharmacokinetics | Half-life extension to 6-8 days via albumin binding | High (Clinical Trials) |
| Pulsatility Modeling | Preservation of physiological GH pulsatile secretion | Moderate (Human Trials) |
| Growth Normalization | Restoration of weight and length in deficiency models | Moderate (Animal Model) |
| Metabolic Stability | Resistance to DPP-4 and proteolytic cleavage | High (In Vitro) |
Domain-Specific Observations
1. Sustained GH and IGF-1 Elevation
Research by Teichman et al. (2006) demonstrated that a single injection of CJC-1295 DAC resulted in dose-dependent increases in mean plasma GH for up to 6 days and IGF-1 for up to 10 days [1]. Multiple administrations showed cumulative effects, suggesting that the compound allows for sustained elevation of the GH/IGF-1 axis in lab settings.
2. Preservation of Pulsatile Secretion
A key observation in CJC-1295 research is its effect on the "pulsatility" of GH. Unlike GH secretagogues (GHS) that may force peak release, CJC-1295 raises the basal concentration (the "troughs" between pulses) while allowing natural hypothalamic signals to continue triggering peaks [2]. This results in a higher mean GH concentration without blunting the physiological pulse frequency.
3. Metabolic and Protective Effects
In animal models, specifically GHRH-knockout mice, Alba et al. observed that once-daily administration of CJC-1295 restored normal growth trajectories and body composition [3]. These findings suggest that long-acting GHRH analogs may serve as viable tools for investigating metabolic disorders and GH deficiencies in specialized RUO environments.
Pharmacokinetic Comparison: DAC vs. Non-DAC
Researchers often distinguish between "CJC-1295 DAC" and "Mod GRF 1-29" (also referred to as CJC-1295 without DAC).
- CJC-1295 DAC: Covalent binding to albumin; 6-8 day half-life. Investigated for chronic elevation studies.
- Modified GRF 1-29 (Non-DAC): No albumin binding; ~30 minute half-life. Investigated for acute pulsatile modeling, often combined with compounds like Ipamorelin to research synergistic GH surges.
Limitations and Research Directions
While CJC-1295 provides a powerful tool for somatotropic research, its use is strictly confined to laboratory settings. There is a lack of long-term (multi-year) data on the effects of sustained trough elevation in GH/IGF-1 levels. Future research directions include investigating potential synergies with BPC-157 in tissue repair models or combining GHRH analogs with neuroprotective agents like Semax to investigate the GH axis effect on cognitive resilience.
Related Research Compounds
- Tesamorelin: A GHRH analog with a hexenoyl group, investigated for its effects on abdominal adiposity.
- Sermorelin (GRF 1-29): The parent fragment of CJC-1295 with a short half-life (~7-10 min).
- Ipamorelin: A ghrelin mimetic often studied in conjunction with GHRH analogs to explore pituitary GH pulse amplification.
- TB-500: Investigated for its regenerative properties and often cross-referenced in recovery-focused peptide clusters like TB-500.
Where to Source CJC-1295 for Research
For laboratory researchers seeking verified peptide compounds, sourcing from reputable RUO suppliers is critical for experimental consistency. The following institutions provide high-purity peptides for in vitro and in vivo studies:
- Short Chain Aminos – https://shortchainaminos.io
- BioPep – https://biopep.io/
- Catalyst Research – https://catalyst-research.net
- Apex Research Services – https://apexresearchservices.org
Frequently Asked Questions
How does CJC-1295 DAC differ from Modified GRF 1-29?
CJC-1295 DAC contains a Drug Affinity Complex that allows it to covalently bind to serum albumin, extending its research half-life to 6-8 days. In contrast, Modified GRF 1-29 (non-DAC) lacks this complex, resulting in a short half-life of approximately 30 minutes, which is utilized for modeling acute, pulsatile growth hormone release.
What is the primary mechanism of action for CJC-1295?
CJC-1295 acts as a synthetic GHRH (Growth Hormone Releasing Hormone) receptor agonist. It binds to GHRH receptors in the anterior pituitary, activating the adenylyl cyclase/cAMP pathway and protein kinase A (PKA). This signaling cascade stimulates the production and secretion of endogenous growth hormone while preserving physiological pulsatility.
Does CJC-1295 abolish natural growth hormone pulses?
Based on research by Ionescu and Frohman (2006), CJC-1295 does not abolish natural pulses. Instead, it raises the basal or 'trough' levels of growth hormone while traditional peak pulses continue to occur. This leads to a higher overall mean 24-hour concentration of growth hormone and a subsequent sustained elevation in IGF-1.
What amino acid substitutions were used to create CJC-1295?
CJC-1295 is a tetrasubstituted analog of GRF 1-29. The modifications include D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27. These substitutions protect the peptide from rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and other proteases.
Can CJC-1295 be used for human clinical administration?
CJC-1295 is currently limited to laboratory research settings only. There are no approved human or veterinary dosing protocols for this compound. All research involving GHRH analogs must adhere strictly to established lab safety protocols and regulatory guidelines.
Works Cited
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. PMID: 16352683.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone and insulin-like growth factor-I response to CJC-1295, a long-acting analog of growth hormone-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1285. PMID: 17018654.
- Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH-knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. doi: 10.1152/ajpendo.00201.2006. PMID: 16822960.
- Jette L, et al. GC1101, a long-acting GHRH analog, stimulates GH and IGF-I secretion in healthy volunteers. Proteomics Clin Appl. 2009 Apr;3(4):462-72. doi: 10.1002/prca.200800049. PMID: 19386527.
- Campbell RM, et al. Enhanced growth hormone-releasing activity of a cyclized growth hormone-releasing factor analog, [Ala15, Leu27]hGRF(1-29)NH2. Peptides. 1994;15(3):489-495. PMID: 8065842.